Clinical trials: Haploidentical Stem Cell Transplantation
Hematopoietic/Lymphoid Cancer
Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor
This phase II trial studies how well total-body irradiation, donor lymphocyte infusion, and cyclophosphamide before donor stem cell transplant works in treating patients with high-risk hematologic malignancies.
- Trial name
- NCT01982682
- Testing
- Total-Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Cyclophosphamide
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Leukemia, Lymphocytic, Acute, Leukemia, Lymphocytic, Chronic
Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit
This study is a means of providing transplantation to those patients who would be a stem cell transplant candidate who do not have an appropriate donor.
- Conditions
- Leukemia, Lymphocytic, Acute, Leukemia, Lymphocytic, Chronic, Leukemia, Myelocytic, Acute, Leukemia, Myeloid, Chronic
- Trial name
- Haplo/Cord (NCT01050946)
- Testing
- Haploidentical/cord transplant
- Volunteers
- 1 people
- Sponsor
- Medical College of Wisconsin
Hematologic Malignancy
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
The purpose of this research study is to examine the survival of patients undergoing partially matched hematopoietic stem cell transplant (HSCT) on a new type of treatment approach, which has been developed specifically for…
- Trial name
- NCT01341301
- Testing
- Total Body Irradiation, Donor Lymphocyte Infusion (DLI), Cyclophosphamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Blood Stem Cell Transplant Failure, Leukemia
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
The goal of this clinical research study is to learn about the safety of giving a stem cell transplant from a tissue-mismatched donor, followed by cyclophosphamide, to patients with certain types of blood disorders or blood…
- Conditions
- Blood Stem Cell Transplant Failure, Leukemia, Hematologic Malignancies
- Trial name
- NCT01010217
- Testing
- Cyclophosphamide, Fludarabine, Melphalan
- Where
- United States
- Volunteers
- 176 people
- Sponsor
- M.D. Anderson Cancer Center
Hematological Malignancies
Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen
In this study, participants with high-risk hematologic malignancies undergoing hematopoietic cell transplantation (HCT), who do not have a suitable human leukocyte antigen (HLA)-matched related/sibling donor (MSD), matched…
- Trial name
- NCT02199041
- Testing
- Cyclophosphamide, Thiotepa, Fludarabine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- St. Jude Children's Research Hospital
Leukemia, Acute Lymphocytic (ALL), Leukemia, Myeloid, Acute(AML)
Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies
Blood and marrow stem cell transplant has improved the outcome for patients with high-risk hematologic malignancies. However, most patients do not have an appropriate HLA (immune type) matched sibling donor available and/or are…
- Conditions
- Leukemia, Acute Lymphocytic (ALL), Leukemia, Myeloid, Acute(AML), Leukemia, Myeloid, Chronic(CML), Juvenile Myelomonocytic Leukemia (JMML)
- Trial name
- NCT00566696
- Testing
- CliniMACS, Stem cell transplantation, Fludarabine
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- St. Jude Children's Research Hospital
Graft-versus-host Disease
Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention
This is a single arm, open label, optimal 2-stage Simon design phase Ib-II clinical trial. Adult patients with hematological malignancies undergoing allogeneic HSCT from first- or second-degree haploidentical donor are eligible…
- Trial name
- NCT04503616
- Testing
- Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- NYU Langone Health
Hematologic Neoplasms, Graft-Versus-Host Disease
Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT)
The purpose of this study is to determine the safety and efficacy of post-transplant cyclophosphamide and a post-transplant infusion of donor cells, that have been specially processed to remove alpha beta t-cells, in patients…
- Trial name
- ABD (NCT02193880)
- Testing
- Alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Ayman Saad
Leukemia, Chronic Myelogenous Leukemia
Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG
The goal of this clinical research study is to learn if giving a kind of immune cell called natural killer (NK) cells after chemotherapy will improve the response to a stem cell transplant in patients with CML.
- Trial name
- NCT01390402
- Testing
- Fludarabine, Busulfan, NK cell infusion:
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Biphenotypic Leukemia, Acute Erythroid Leukemia in Remission
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
This phase II trial studies how well donor peripheral blood stem cell (PBSC) transplant works in treating patients with hematologic malignancies.
- Conditions
- Acute Biphenotypic Leukemia, Acute Erythroid Leukemia in Remission, Acute Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission
- Trial name
- NCT01028716
- Testing
- Cyclophosphamide, Filgrastim, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Fred Hutchinson Cancer Center
Severe Aplastic Anemia
Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)
This study is a prospective, multicenter phase II study with patients receiving haploidentical transplantation for Severe Aplastic Anemia (SAA).
- Trial name
- CHAMP (NCT02918292)
- Testing
- Antithymocyte Globulin (ATG), Fludarabine, Cyclophosphamide
- Where
- 28 sites in United States
- Volunteers
- 32 people
- Sponsor
- Medical College of Wisconsin
Leukemia, Lymphoma
Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy
In this study, participants with high-risk hematologic malignancies undergoing hematopoietic cell transplantation (HCT), who do not have a suitable human leukocyte antigen (HLA) matched related/sibling donor (MSD) or matched…
- Trial name
- NCT01807611
- Testing
- Total Lymphoid Irradiation, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- St. Jude Children's Research Hospital
Lymphoma
TCR-α/β and CD19 Depleted Stem Cell Grafts From Haplo Donors for HSCT in Relapsed Lymphoma
To determine engraftment of neutrophils and platelets at 28 days following alpha/beta T-cell and CD19 cell depletion using Human Leukocyte Antigen (HLA) haploidentical donors for peripheral blood stem cell transplant in relapsed…
- Trial name
- NCT02652468
- Testing
- Fludarabine Phosphate, Mesna, Cyclophosphamide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Wisconsin, Madison
Primary Immune Deficiency Disorder, Hematopoietic Stem Cell Transplantation
TCR Alpha/Beta Depletion for HSCT From Haploidentical and Unrelated Donors in the Treatment of PID
Treatment Study to assess of safety and efficiency of T cells receptor (TCR) alfa beta depleted graft for hematopoietic stem cell transplantation (HSCT) from haploidentical and unrelated donors in patients with primary…
- Trial name
- NCT02327351
- Testing
- Biological: TCR alfa beta T cell depletion
- Where
- Russia
- Volunteers
- 98 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Hematologic Malignancy
Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor
This study will test whether half matched donors with favorable KIR genes will reduce the risk of cancer recurring after transplant.
- Trial name
- NCT02880293
- Testing
- melphalan, fludarabine, thiotepa
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Sickle Cell Disease
SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCD
Related donor stem cell transplantation using the alemtuzumab/ TBI platform has been shown to be a safe strategy to cure severe sickle cell disease.
- Trial name
- SCD-Haplo (NCT02013375)
- Testing
- Haploidentical Transplant, Alemtuzumab, Total Body Irradiation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Damiano Rondelli, MD
Hematologic Malignancies
A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative
The purpose of this study is to develop a way of treating patients who do not have a completely matched family donor or a readily available unrelated donor with bone marrow transplant by using a partially-matched family donor.
- Trial name
- NCT00429143
- Testing
- Total Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Cyclophosphamide (CY)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Acute Lymphoblastic Leukemia, Non Hodgkins Lymphoma
T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts
Subjects are being asked to participate in this study because treatment of their disease requires them to receive a stem cell transplant.
- Conditions
- Acute Lymphoblastic Leukemia, Non Hodgkins Lymphoma, Myelodysplastic Syndrome, Acute Myeloid Leukemia
- Trial name
- MOHEL (NCT00368355)
- Testing
- Ara-C, Cyclophosphamide, Campath-1H
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Baylor College of Medicine
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With Immediate Haploidentical Plus Unrelated Cord Donor Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS Patients
The study seeks to compare time from formal search to hematopoietic cell transplantation (HCT) for patients 18 years and older, randomized between haplo-cord search and matched unrelated donor (MUD) search for patients with acute…
- Trial name
- NCT02648932
- Testing
- Haplo-Cord Transplant, Matched Unrelated Donor Transplant
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Chicago
Hematologic Malignancies
Stem Cell Transplant for Hematologic Diseases
Patients are being asked to participate in this study because they have a cancer in their blood, Fanconi's Anemia, or have been unsuccessfully treated for bone marrow failure such as Aplastic Anemia or Paroxysmal Nocturnal…
- Trial name
- HIMSUM (NCT00058825)
- Testing
- Campath 1H, Fludarabine, Stem Cell Transplant
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Baylor College of Medicine